No Data
No Data
Dyne Therapeutics Insider Sold Shares Worth $1,334,201, According to a Recent SEC Filing
Susanna Gatti High, Chief Operating Officer, on June 12, 2024, sold 40,000 shares in Dyne Therapeutics (DYN) for $1,334,201. Following the Form 4 filing with the SEC, High has control over a total of
Dyne Therapeutics(DYN.US) Officer Sells US$1.33 Million in Common Stock
$Dyne Therapeutics(DYN.US)$ Officer HIGH SUSANNA GATTI sold 40,000 shares of common stock on Jun 12, 2024 at an average price of $33.36 for a total value of $1.33 million.Source: Announcement What is
Express News | Dyne Therapeutics DYNE-302 Exhibited Prolonged Activity In Preclinical Facioscapulohumeral Muscular Dystrophy Models; Presents Data During FSHD Society International Research Congress
Dyne Therapeutics Presents New Preclinical Data for Its Facioscapulohumeral Muscular Dystrophy Program During the FSHD Society International Research Congress
Dyne Therapeutics, Inc. (Nasdaq: DYN) today highlighted new preclinical data for DYNE-302, its product candidate for facioscapulohumeral muscular dystrophy (FSHD), that demonstrated robust and durable DUX4 suppression and functional benefit.
Morgan Stanley Maintains Dyne Therapeutics(DYN.US) With Buy Rating, Maintains Target Price $48
Morgan Stanley analyst Michael Ulz maintains $Dyne Therapeutics(DYN.US)$ with a buy rating, and maintains the target price at $48.According to TipRanks data, the analyst has a success rate of 40.8% an
Casey's Reports Upbeat Earnings, Joins Avidity Biosciences, Rentokil Initial And Other Big Stocks Moving Higher On Wednesday
U.S. stocks were higher, with the Nasdaq Composite gaining over 250 points on Wednesday. Shares of Casey's General Stores, Inc. rose sharply during Wednesday's session after the company reported earnings.